Sinovac Biotech announced the start of a Phase III trial of CoronaVac, its COVID-19 vaccine, in Turkey. The trial will first enroll 1,300 healthcare workers between the ages of 18-59, who will receive two doses of vaccine or placebo at a two-week interval. Then it will enroll 12,000 members of the general public under the same protocol. Sinovac has also completed China Phase I/II trials of the vaccine in adults and elderly people with seroconversion rates above 90%. The vaccine was well-tolerated, Sinovac added. More details.... Stock Symbol: (NSDQ: SVA) Share this with colleagues: // //